- Home
- MLYS vs NGL Comparison
MLYS vs NGL Comparison
Compare MLYS & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- NGL
- Stock Information
- Founded
- MLYS 2019
- NGL 1940
- Country
- MLYS United States
- NGL United States
- Employees
- MLYS N/A
- NGL N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- NGL Natural Gas Distribution
- Sector
- MLYS Health Care
- NGL Utilities
- Exchange
- MLYS Nasdaq
- NGL Nasdaq
- Market Cap
- MLYS 590.3M
- NGL 564.5M
- IPO Year
- MLYS 2023
- NGL 2011
- Fundamental
- Price
- MLYS $11.87
- NGL $4.46
- Analyst Decision
- MLYS Strong Buy
- NGL
- Analyst Count
- MLYS 2
- NGL 0
- Target Price
- MLYS $30.00
- NGL N/A
- AVG Volume (30 Days)
- MLYS 255.3K
- NGL 296.4K
- Earning Date
- MLYS 11-11-2024
- NGL 11-12-2024
- Dividend Yield
- MLYS N/A
- NGL N/A
- EPS Growth
- MLYS N/A
- NGL N/A
- EPS
- MLYS N/A
- NGL N/A
- Revenue
- MLYS N/A
- NGL $6,239,231,000.00
- Revenue This Year
- MLYS N/A
- NGL N/A
- Revenue Next Year
- MLYS N/A
- NGL $3.50
- P/E Ratio
- MLYS N/A
- NGL N/A
- Revenue Growth
- MLYS N/A
- NGL N/A
- 52 Week Low
- MLYS $6.06
- NGL $3.84
- 52 Week High
- MLYS $16.91
- NGL $6.20
- Technical
- Relative Strength Index (RSI)
- MLYS 41.32
- NGL 56.73
- Support Level
- MLYS $11.30
- NGL $3.84
- Resistance Level
- MLYS $13.06
- NGL $4.55
- Average True Range (ATR)
- MLYS 1.01
- NGL 0.21
- MACD
- MLYS -0.22
- NGL 0.05
- Stochastic Oscillator
- MLYS 14.43
- NGL 86.62
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, and for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.